Press release

June 29, 2020
1 min read

Vyome’s acne treatment demonstrates positive phase 2 results


Press release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

VB-1953, a first-in-class topical bactericidal and TLR-MD2 inhibitor, showed a statistically significant difference in inflammatory lesions in the treatment of moderate to severe acne, according to a press release from Vyome Therapeutics.

The phase 2 randomized, multicenter, double-blind, dose-ranging trial evaluated the safety and efficacy of VB-1953 gel when applied once or twice daily for 12 weeks. It included 471 subjects across 13 U.S. sites.

“These results demonstrate that VB-1953, with its dual mechanism of action directly killing resistant and non-resistant C. acnes strains while blocking inflammation through TLR-MD2 inhibition, has the potential to become a safe and effective topical treatment for facial acne and an alternative to oral systemic drugs,” Shiladitya Sengupta, PhD, scientific co-founder of Vyome, said in the release.

In the intent to treat group, the mean absolute inflammatory lesion change in the VB-1953 once-daily group was 20.4 compared with 17.8 in the vehicle group (P < .003). In the per protocol group, the mean change was 20.4 in the treatment arm and 16.6 in the vehicle arm (P < .001).

“We are very pleased to have met the primary endpoint of the study and to demonstrate the continued safety of the molecule. Patients need a highly effective drug, and our data shows a very high response, and our data shows a very high response, which is encouraging as we plan to advance to phase 3 with a once-daily dose,” Vyome CEO Venkat Nelabhotla said in the release.